Abstract:BACKGROUND: Mitochondrial dysfunction and oxidative stress are closely associated with the pathogenesis of Parkinson's disease. Peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC-1α) is thought to play multiple roles in the regulation of mitochondrial biogenesis and cellular energy metabolism. We recently reported that altering PGC-1α gene expression modulates mitochondrial functions in N-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>) treated human SH-SY5Y neuroblastoma cells, possibly via the regulation of Estrogen-related receptor α (ERRα), nuclear respiratory factor 1 (NRF-1), nuclear respiratory factor 2 (NRF-2) and peroxisome proliferator-activated receptor γ (PPARγ) expression. In the present study, we aimed to further investigate the potential beneficial effects of PGC-1α in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated C57BL mice.METHODS: The overexpression or knockdown of the PGC-1α gene in the mouse model of dopaminergic neurotoxicity was performed using a stereotactic injection of lentivirus in MPTP-treated male C57BL/6 mice. Mice were randomly assigned to one of 6 groups (n=24 per group): normal saline (NS) intraperitoneal injection (i.p.) (con); MPTP i.p. (M); solvent of the lentivirus striatal injection (lentivirus control) + MPTP i.p. (LVcon+M); lentivirus striatal injection + MPTP i.p. (LV+M); LV-PGC-1α striatum injection + MPTP i.p. (LVPGC+M); and LV-PGC-1α-siRNA striatal injection + MPTP i.p. (LVsiRNA+M). Intraperitoneal injections of MPTP/NS were conducted two weeks after lentivirus injection.RESULTS: We found significant improvement in motor behavior and increases in tyrosine hydroxylase expression in the substantia nigra (SN) in the brains of mice in the LVPGC+M group. The opposite tendency was observed in those in the LVsiRNA+M group. The expression of superoxide dismutase (SOD) in the SN region was also consistent with the changes in PGC-1α expression. Electron microscopy showed an increasing trend in the mitochondrial density in the LVPGC+M group and a decreasing trend in the M and LVsiRNA+M groups compared to that in the controls.CONCLUSIONS: Our results indicated that PGC-1α rescues the effects of MPTP-induced mitochondrial dysfunction in C57BL mice.

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.

[Effects of Chronic, Systemic Treatment with Metabotropic Glutamate Receptor 5 Antagonist on Behavioral Activity and Neuroprotection in a Preclinical Rat Model of Parkinson's Disease].

Blockade of Mglur5 Reverses Abnormal Firing of Subthalamic Nucleus Neurons in 6-Hydroxydopamine Partially Lesioned Rats.

MPTP-Induced Impairment of Cardiovascular Function

L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the Mglur5 Antagonist MPEP in 6-Ohda-lesioned Rats.

Antidyskinetic Treatment with the mGluR5 Antagonist MPEP Affects CaMKII/CREB/BDNF Molecular Pathways in the Parkinsonian Striatum

Effects of Metabotropic Glutamate Receptor 5 Antagonist MPEP on Behaviors and Striatal Postsynaptic Density-95 Protein Expression in Rats with Levodopa-Induced Dyskinesia

Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum

Antagonism of metabotropic glutamate receptor type 5 prevents levodopa‐induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence

Effects of Chronic, Systemic Treatment with the Dopamine Receptor Agonist R-apomorphine in Partially Lesioned Rat Model of Parkinson's Disease: an Electrophysiological Study of Substantia Nigra Dopamine Neurons.

Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease

Distinct Anti-Dyskinetic Effects of Amantadine and Group II Metabotropic Glutamate Receptor Agonist LY354740 in a Rodent Model: an Electrophysiological Perspective

Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice

Beneficial effects of PGC-1α in the substantia nigra of a mouse model of MPTP-induced dopaminergic neurotoxicity

Activation of mGlu 2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression

Smilagenin Protects Dopaminergic Neurons in Chronic MPTP/Probenecid-Lesioned Parkinson's Disease Models

N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson’s Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF

Neuroprotective Effects of Pramipexole Transdermal Patch in the MPTP-induced Mouse Model of Parkinson's Disease

Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model

Comparative Effects of Acute or Chronic Administration of Levodopa to 6-OHDA-lesioned Rats on the Expression and Phosphorylation of N -methyl- d -aspartate Receptor NR1 Subunits in the Striatum